Sino Biopharm Signs Major Global License Deal with Sanofi for Rovadicitinib

Key Points from the Announcement

• Sino Biopharmaceutical Limited (Stock code: 1177) has entered into an exclusive global license agreement with Sanofi for the development, manufacturing, and commercialization of its JAK/ROCK inhibitor, rovadicitinib.
• The deal is executed via Sino Biopharm’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), and a fully owned subsidiary of Sanofi S.A.
• Sino Biopharm will grant Sanofi exclusive global rights to develop, manufacture, and commercialize rovadicitinib.
• The deal includes an upfront payment of US\$135 million and potential milestone payments (development, regulatory, and sales) of up to US\$1.395 billion.
• Sino Biopharm is also eligible to receive double-digit tiered royalties on annual net sales of rovadicitinib.
• The agreement is subject to customary closing conditions, including regulatory clearances.

Details of the Exclusive License Agreement

The agreement marks a significant step for Sino Biopharm in partnering with a global pharmaceutical leader, Sanofi, to maximize the global potential of rovadicitinib. The terms of the deal are highly favorable and could be transformational for Sino Biopharm’s future revenues and global footprint.

• Upfront Payment: US\$135 million cash injection upon closing.
• Milestone Payments: Potential to receive up to US\$1.395 billion based on developmental, regulatory, and sales achievements.
• Royalties: Double-digit tiered royalties on annual net sales, potentially providing long-term recurring revenue.
• Global Reach: Sanofi will take on worldwide development, manufacturing, and commercialization responsibilities, providing Sino Biopharm access to Sanofi’s global commercial and clinical infrastructure.

About Rovadicitinib

Rovadicitinib, a first-in-class, novel, potent oral small-molecule JAK/ROCK inhibitor, is positioned as a potential global blockbuster:

• Dual Mechanism of Action: Inhibits both JAK/STAT and ROCK pathways, offering synergistic anti-inflammatory and anti-fibrotic effects.
• Immunological Impact: Suppresses inflammatory signaling, reduces overactive T helper cells, and enhances regulatory T cell function, restoring immune homeostasis.

Regulatory and Clinical Progress

• In February 2026, rovadicitinib (Brand name: Anxu®) received China NMPA approval as a first-line treatment for adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF).
• Rovadicitinib is in a Phase III trial in China for chronic graft-versus-host disease (cGVHD) and was granted Breakthrough Therapy Designation by the CDE in August 2025.
• In the United States, the drug has entered Phase II clinical studies for cGVHD.
• Phase Ib/IIa data published in Blood show superior 12-month failure-free survival (FFS) and efficacy in fibrosis-dominated organs compared to other approved therapies, with potential to overcome ruxolitinib resistance.

Why This Is Important for Shareholders

This agreement is highly significant and likely to be price-sensitive for several reasons:

• Immediate Financial Impact: The upfront payment provides a substantial boost to Sino Biopharm’s cash position.
• Milestone and Royalty Potential: If rovadicitinib succeeds in global markets, milestone and royalty payments could provide substantial ongoing revenue, supporting future growth and potentially higher dividends.
• Validation by Sanofi: Partnering with a global leader like Sanofi validates the scientific and commercial potential of rovadicitinib, potentially enhancing Sino Biopharm’s profile and valuation.
• Risk Mitigation: The deal allows Sino Biopharm to leverage Sanofi’s expertise and resources, reducing the financial and operational risk of global commercialization.
• Regulatory Success: With recent approvals and designations in China and the U.S., the probability of clinical and commercial success is strengthened.

Leadership and Governance

The Board of Sino Biopharm is led by Chairwoman Ms. Tse, Theresa Y Y, with a mix of experienced executive and independent directors, reflecting strong corporate governance.

Conclusion

The exclusive license deal with Sanofi represents a major value-creating opportunity for Sino Biopharm and is likely to be viewed as highly positive by the market. The combination of upfront cash, potential for large milestone payments, ongoing royalties, and validation by a top-tier partner could significantly impact the company’s near- and long-term valuation. Investors should monitor the closing of this agreement and ongoing clinical and regulatory developments related to rovadicitinib.

Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence or consult a licensed financial advisor before making any investment decisions. The information is based on the latest company announcement as of March 4, 2026, and may be subject to updates or changes.

View SINO BIOPHARM Historical chart here